Blockade drugs targeting the PD1/PDL1 signaling pathway have brought novel insights into the treatment strategies and exhibit relatively satisfactory efficiency across multiple tumors, including breast cancer, colon cancer, bladder cancer, advanced gastric cancer, and kidney cancer (30–32). The gene discussed is CD274; the disease is kidney cancer.